Products in Development
Evofem Biosciences® is dedicated to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary vaginal pH modulator to develop product candidates for multiple indications, including the prevention of urogenital transmission of chlamydia and gonorrhea in women and recurrent bacterial vaginosis.
EVO100 – an investigational candidate for the prevention of urogenital chlamydia and gonorrhea in women
- Balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria
- Using a different mechanism of action that may help to address drug resistance concerns
The Phase 2b AMPREVENCE study evaluating EVO100 for the prevention of chlamydia and gonorrhea met its primary and secondary endpoints, and the study showed that EVO100 was generally safe and well tolerated. Results of this double-blinded, placebo-controlled trial were presented at the 2020 STD Prevention Virtual Conference (view poster).
EVO100 has been granted Fast Track Designation for the prevention of chlamydia in women and is designated a Qualified Infectious Disease Product (QIDP) for the prevention of gonorrhea in women by the U.S. Food and Drug Administration.
Vaginal pH modulator for the prevention of recurrent Bacterial Vaginosis (BV)
- Kill BV-associated pathogenic bacteria, which has been demonstrated in vitro
- Balance vaginal pH, thereby supporting normal vaginal flora and eliminating odor associated with BV
These products have not been approved for marketing by the U.S. Food and Drug Administration or any other regulatory agency.